Analysis of whether vorasidenib-VORANIGO can be used in the treatment of patients with grade 3 glioma

Vorasidenib (trade name VORANIGO) is a new type of small molecule targeted drug that mainly targets IDH1 and IDH2 mutant tumors. IDHmutations are common in low-grade gliomas and some high-grade gliomas. By inhibiting the activity of mutant IDHenzyme, voroxanib can block 2-< /span>Hydroxyglutarate (2-HG) accumulates in tumor cells, thereby interfering with tumor metabolism and growth, providing targeted treatment options for patients with IDH mutant glioma.

Clinical research is still ongoing for grade III glioma (WHOgrade III glioma). Vorsidenib has shown potential to slow tumor progression and improve progression-free survival in low-grade gliomas, but efficacy data in grade III gliomas are relatively limited. Due to the high malignancy of grade III gliomas, the efficacy of a single targeted drug may be affected by tumor heterogeneity and enhanced invasiveness, and its use needs to be evaluated based on specific pathological types and IDH mutation status.

The potential advantage of using voroxiranib to treat grade 3 gliomas lies in its precise mechanism for targeting IDH mutations, which can reduce damage to normal cells and has relatively less toxic side effects than traditional radiotherapy or chemotherapy. In addition, vorsidenib is administered orally and has good patient compliance, and may delay disease progression in early or postoperative adjuvant treatment, providing a new adjuvant treatment strategy for patients with grade III glioma.

In general, vorsidenib has potential therapeutic value for patients with IDH mutated grade III gliomas, but current evidence mainly comes from early clinical studies and low-grade glioma trial results. In practical applications, it is necessary to combine the pathological classification, IDH mutation status and the overall condition of the patient, and have a professional neuro-oncology team evaluate the feasibility, and cooperate with imaging monitoring and treatment response assessment to ensure efficacy and safety.

Reference materials:https://www.drugs.com/